Document Detail

Clash of the microbes: let's bring back the good guys.
MedLine Citation:
PMID:  23321673     Owner:  NLM     Status:  MEDLINE    
A 38-year-old man with a history of HIV infection virologically suppressed on antiretroviral therapy presents to his gastroenterologist for evaluation of iron deficiency anemia and weight loss. A diagnostic colonoscopy demonstrates a two-centimeter ulcerated mass in the cecum. Biopsies of the lesion return moderately differentiated adenocarcinoma that is wild type for the KRAS mutation by real-time PCR.
Martin J Wolff; Michael A Poles; Judith A Aberg
Related Documents :
19349983 - A genome-wide association study identifies variants in the hla-dp locus associated with...
7548923 - Histopathology of chronic viral hepatitis: guidelines for a revised classification.
22546723 - Effects of first antiretroviral regimen on lipid levels in hiv (+) individuals.
Publication Detail:
Type:  Comment; Journal Article     Date:  2013-01-16
Journal Detail:
Title:  The Journal of clinical investigation     Volume:  123     ISSN:  1558-8238     ISO Abbreviation:  J. Clin. Invest.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-04-19     Completed Date:  2013-05-13     Revised Date:  2014-01-09    
Medline Journal Info:
Nlm Unique ID:  7802877     Medline TA:  J Clin Invest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  544-5     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Retroviral Agents / administration & dosage*
Gastrointestinal Tract / immunology*
Probiotics / administration & dosage*
Simian Acquired Immunodeficiency Syndrome / immunology*,  therapy*
Reg. No./Substance:
0/Anti-Retroviral Agents; 0/Prebiotics
Comment On:
J Clin Invest. 2013 Feb 1;123(2):903-7   [PMID:  23321668 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Loss of SPARC in bladder cancer enhances carcinogenesis and progression.
Next Document:  mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice.